no news_id given

BioFunding

04.12.2009

Luxembourg – Billions of euros spent on so-called Networks of Excellence (NoEs) during the EU’s 6th Framework Programme appear to have brought little return. A new study by the European Court of Auditors has revealed that the...

BioPeople

04.12.2009

The management team at London Genetics Ltd has undergone some changes. Dr. Barrie Ward, formerly with GlaxoSmith Kline, will now act as Chairman of the British pharmacogenetics specialist. Dominique Kleyn, who led business...

Politics / Law

03.12.2009

With policymakers deep in discussions on a replacement for the Kyoto Protocol, the World Wildlife Fund (WWF) and Danish white biotech firm Novozymes have together calculated what biotech can contribute to reducing emissions of...

BioPeople, UKUK

02.12.2009

Dr. Laurence Barker will take over the newly created role of Head of Business Development at Syntaxin. He joins the drug developer from MorphoSys AG, where he held the position of Associate Director, Business Development. Prior...

Miscellaneous

02.12.2009

Bejing/Brussels – China is the first country in the world to begin the commercialisation of a locally developed genetically modified (GM) rice variety. On 1 December, the Chinese Ministry of Agriculture officially approved...

Politics / Law

01.12.2009

With the authorisation on November 30 of the genetically modified (GM) maize MIR604, the European Commission has fulfilled the final requests made by US farming lobby groups and their European counterparts regarding the maize....

BioFunding

01.12.2009

Brussels – The European Research Council (ERC) has launched a call to attract top international researchers to EU labs (more...). The proposal deadline for the life sciences arm of the Advanced Investigators Grants, which foresee...

BioPeople, BeNeLuxBelgiumNetherlandsLuxembourg

01.12.2009

Jörn Aldag took the helm at Amsterdam Molecular Therapies on October 5th. The company’s new Chief Executive Officer brings along 25 years of experience in corporate management and finance. As the former President and CEO of...

Politics / Law

30.11.2009

Brussels – John Dalli from Malta will be given almost all-important competencies, in the area of biotechnology in the next European Commission. The re-elected Commission President Manuel Barroso has concentrated a huge array of...

Displaying results 361 to 370 out of 1983

< Previous 361-370 Next >

© 2007-2015 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive/browse/36.html

Video

All videos

Product of the week

Products

WhitePaper

LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Events

All Events

Partner-Events

München

BioVaria 2015

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...

Stock list

All quotes

TOP

  • WILEX3.59 EUR5.59%
  • BASILEA118.10 CHF3.14%
  • PAION2.58 EUR2.79%

FLOP

  • BIOTEST79.20 EUR-19.51%
  • CYTOS1.01 CHF-8.18%
  • FORMYCON28.00 EUR-6.01%

TOP

  • CO.DON3.15 EUR22.1%
  • WILEX3.59 EUR21.3%
  • FORMYCON28.00 EUR21.0%

FLOP

  • CYTOS1.01 CHF-27.9%
  • BIOTEST79.20 EUR-18.1%
  • THERAMETRICS0.07 CHF-12.5%

TOP

  • SANTHERA98.85 CHF2460.9%
  • CYTOS1.01 CHF676.9%
  • WILEX3.59 EUR337.8%

FLOP

  • MOLOGEN5.07 EUR-54.8%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.41 EUR-28.1%

No liability assumed, Date: 26.04.2015

Current issue

All issues